阿利西尤单抗对急性冠脉综合征后脂蛋白(a)与心血管风险的影响
ODYSSEY Outcomes 试验预设分析纳入 18,924 例近期急性冠脉综合征且接受高强度他汀治疗的患者,随机接受阿利西尤单抗或安慰剂,中位随访 2.8 年。结果显示基线脂蛋白(a)和校正 LDL-C 可预测主要不良心血管事件,阿利西尤单抗降低脂蛋白(a) 5.0 mg/dl、校正 LDL-C 51.1 mg/dl,并降低 MACE 风险(HR 0.85;95%CI 0.78–0.93),且脂蛋白(a)降低独立预测 MACE 风险下降。
要点
- 基线脂蛋白(a)和校正 LDL-C 水平均可预测 ACS 后 MACE 风险。
- 阿利西尤单抗降低脂蛋白(a)与校正 LDL-C,并减少 MACE(HR 0.85)。
- 阿利西尤单抗诱导的脂蛋白(a)降低独立贡献于 MACE 风险下降。
核心结论
- 基线脂蛋白(a)和校正 LDL-C 水平及其经阿利西尤单抗的降低幅度可预测近期 ACS 后 MACE 风险。
- 阿利西尤单抗降低脂蛋白(a)是 MACE 风险降低的独立贡献因素,提示脂蛋白(a)应作为 ACS 后独立治疗靶点。
研究设计与样本
- ODYSSEY Outcomes 试验的预设分析,安慰剂对照设计。
- ACS 后 1–12 个月、接受高强度他汀治疗的 18,924 例患者随机接受阿利西尤单抗或安慰剂,中位随访 2.8 年。
- 脂蛋白(a)在随机化时及此后 4 个月和 12 个月测量。
- 主要 MACE 结局为冠心病死亡、非致死性心肌梗死、缺血性卒中或因不稳定性心绞痛住院。
主要发现
- 基线脂蛋白(a)中位数 21.2 mg/dl(IQR 6.7–59.6 mg/dl)和校正 LDL-C 预测 MACE。
- 阿利西尤单抗降低脂蛋白(a) 5.0 mg/dl(IQR 0–13.5 mg/dl),降低校正 LDL-C 51.1 mg/dl(IQR 33.7–67.2 mg/dl)。
- 阿利西尤单抗降低 MACE 风险(HR 0.85;95%CI 0.78–0.93)。
- 调整基线两种脂蛋白浓度及人口学和临床特征后,阿利西尤单抗诱导的脂蛋白(a)和校正 LDL-C 降低独立预测 MACE 风险降低。
- 阿利西尤单抗使脂蛋白(a)每降低 1 mg/dl 对应 HR 0.994(95%CI 0.990–0.999;P=0.0081)。
临床怎么用
- 近期 ACS 且接受高强度他汀治疗的患者,可考虑检测脂蛋白(a)以评估残余风险。
- 阿利西尤单抗降低脂蛋白(a)的程度可独立预测 MACE 风险下降,支持将脂蛋白(a)作为治疗目标进行管理。
局限性
- 原文摘要未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). OBJECTIVES: A pre-specified analysis of the placebo-controlled ODYSSEY Outcomes trial in patients with recent acute coronary syndrome (ACS) determined whether alirocumab-induced changes in lipoprotein(a) and LDL-C independently predicted major adverse cardiovascular events (MACE). METHODS: One to 12 months after ACS, 18,924 patients on high-intensity statin therapy were randomized to alirocumab or placebo and followed for 2.8 years (median). Lipoprotein(a) was measured at randomization and 4 and 12 months thereafter. The primary MACE outcome was coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina. RESULTS: Baseline lipoprotein(a) levels (median: 21.2 mg/dl; interquartile range [IQR]: 6.7 to 59.6 mg/dl) and LDL-C [corrected for cholesterol content in lipoprotein(a)] predicted MACE. Alirocumab reduced lipoprotein(a) by 5.0 mg/dl (IQR: 0 to 13.5 mg/dl), corrected LDL-C by 51.1 mg/dl (IQR: 33.7 to 67.2 mg/dl), and reduced the risk of MACE (hazard ratio [HR]: 0.85; 95% confidence interval [CI]: 0.78 to 0.93). Alirocumab-induced reductions of lipoprotein(a) and corrected LDL-C independently predicted lower risk of MACE, after adjustment for baseline concentrations of both lipoproteins and demographic and clinical characteristics. A 1-mg/dl reduction in lipoprotein(a) with alirocumab was associated with a HR of 0.994 (95% CI: 0.990 to 0.999; p = 0.0081). CONCLUSIONS: Baseline lipoprotein(a) and corrected LDL-C levels and their reductions by alirocumab predicted the risk of MACE after recent ACS. Lipoprotein(a) lowering by alirocumab is an independent contributor to MACE reduction, which suggests that lipoprotein(a) should be an independent treatment target after ACS. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).
引用
- Bittner VA, Szarek M, Aylward PE, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020. PMID: 31948641. doi:10.1016/j.jacc.2019.10.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。